Skip to main content
Erschienen in: Current Atherosclerosis Reports 9/2015

01.09.2015 | Clinical Trials and Their Interpretations (J Kizer, Section Editor)

Role of Fractional-Flow Reserve in Guiding Percutaneous Revascularization in Stable Coronary Artery Disease

verfasst von: Nikolaos Kakouros, Jeffrey J. Rade

Erschienen in: Current Atherosclerosis Reports | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Optimal medical therapy unarguably forms the cornerstone of management for patients with stable coronary artery disease. There is, however, a significant body of evidence suggesting that reduction of ischemia can be achieved more effectively with revascularization than medical therapy and can confer significant symptomatic and prognostic advantages. Nonetheless, owing to limitations of coronary angiography and conventional non-invasive functional testing for myocardial ischemia, targeting of hemodynamically significant coronary stenoses for revascularization is often difficult. We discuss the role of invasive fractional-flow reserve evaluation in guiding percutaneous revascularization procedures for patients with stable coronary artery disease and its potential impact on outcomes for these patients.
Literatur
1.
Zurück zum Zitat GBD Mortality Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef GBD Mortality Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef
2.
Zurück zum Zitat Writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines Circulation 2006;114(10):e385-484. Writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines Circulation 2006;114(10):e385-484.
3.
Zurück zum Zitat Centers for Disease Control and Prevention: National Hospital Ambulatory Medical Care Survey: 2011 Emergency Department Summary Tables. In. Edited by Ambulatory and Hospital Care Statistics Branch; 2015. Centers for Disease Control and Prevention: National Hospital Ambulatory Medical Care Survey: 2011 Emergency Department Summary Tables. In. Edited by Ambulatory and Hospital Care Statistics Branch; 2015.
4.
Zurück zum Zitat Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation. 2004;110(25):3789–94.CrossRefPubMed Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation. 2004;110(25):3789–94.CrossRefPubMed
5.••
Zurück zum Zitat Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949–3003. Latest European Society of Cardiology (ESC) guidelines on the management of stable coronary artery disease. Notably, FFR is given a class I level A recommendation for the identification of hemodynamically relevant coronary lesions, when evidence of ischemia is not available. A Class I Level B recommendation is also given for revascularization of stenoses with FFR <0.80 in patients with angina symptoms or a positive stress test.CrossRef Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949–3003. Latest European Society of Cardiology (ESC) guidelines on the management of stable coronary artery disease. Notably, FFR is given a class I level A recommendation for the identification of hemodynamically relevant coronary lesions, when evidence of ischemia is not available. A Class I Level B recommendation is also given for revascularization of stenoses with FFR <0.80 in patients with angina symptoms or a positive stress test.CrossRef
6.
Zurück zum Zitat Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR); 2012. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR); 2012.
7.
Zurück zum Zitat Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). J Am Coll Cardiol Intv. 2009;2(12):1248–59.CrossRef Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). J Am Coll Cardiol Intv. 2009;2(12):1248–59.CrossRef
8.
Zurück zum Zitat Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–94.CrossRefPubMed Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–94.CrossRefPubMed
9.
Zurück zum Zitat Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–651.CrossRefPubMed Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–651.CrossRefPubMed
10.•
Zurück zum Zitat Fihn SD, Blankenship JC, Alexander KP, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749–67. Latest American Multisociety 2014 guideline update on the management of stable coronary artery disease. Although newest data, including the FAME-2 study, were considered, the recommendations for FFR utilization were not altered from the 2012 full-text guidelines.CrossRefPubMed Fihn SD, Blankenship JC, Alexander KP, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749–67. Latest American Multisociety 2014 guideline update on the management of stable coronary artery disease. Although newest data, including the FAME-2 study, were considered, the recommendations for FFR utilization were not altered from the 2012 full-text guidelines.CrossRefPubMed
11.
Zurück zum Zitat Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart DiseaseA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.CrossRefPubMed Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart DiseaseA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.CrossRefPubMed
12.
Zurück zum Zitat BARI. 2D Study Group: a randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef BARI. 2D Study Group: a randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef
13.
Zurück zum Zitat Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87.CrossRefPubMed Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87.CrossRefPubMed
14.
Zurück zum Zitat Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.CrossRefPubMed Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.CrossRefPubMed
15.
Zurück zum Zitat Boden WE, O'Rourke RA, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151(6):1173–9.CrossRefPubMed Boden WE, O'Rourke RA, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151(6):1173–9.CrossRefPubMed
16.
Zurück zum Zitat Kereiakes DJ, Teirstein PS, Sarembock IJ, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007;50(16):1598–603.CrossRefPubMed Kereiakes DJ, Teirstein PS, Sarembock IJ, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007;50(16):1598–603.CrossRefPubMed
17.
Zurück zum Zitat Kakouros N, Rybicki FJ, Mitsouras D, Miller JM. Coronary pressure-derived fractional flow reserve in the assessment of coronary artery stenoses. Eur Radiol. 2013;23(4):958–67.CrossRefPubMed Kakouros N, Rybicki FJ, Mitsouras D, Miller JM. Coronary pressure-derived fractional flow reserve in the assessment of coronary artery stenoses. Eur Radiol. 2013;23(4):958–67.CrossRefPubMed
18.
Zurück zum Zitat Young DF, Cholvin NR, Roth AC. Pressure drop across artificially induced stenoses in the femoral arteries of dogs. Circ Res. 1975;36(6):735–43.CrossRefPubMed Young DF, Cholvin NR, Roth AC. Pressure drop across artificially induced stenoses in the femoral arteries of dogs. Circ Res. 1975;36(6):735–43.CrossRefPubMed
19.
Zurück zum Zitat Gould KL. Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation. Circ Res. 1978;43(2):242–53.CrossRefPubMed Gould KL. Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation. Circ Res. 1978;43(2):242–53.CrossRefPubMed
20.
Zurück zum Zitat Tu S, Barbato E, Koszegi Z, et al. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. J Am Coll Cardiol Intv. 2014;7(7):768–77.CrossRef Tu S, Barbato E, Koszegi Z, et al. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. J Am Coll Cardiol Intv. 2014;7(7):768–77.CrossRef
21.
Zurück zum Zitat Lima RS, Watson DD, Goode AR, et al. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol. 2003;42(1):64–70.CrossRefPubMed Lima RS, Watson DD, Goode AR, et al. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol. 2003;42(1):64–70.CrossRefPubMed
22.
Zurück zum Zitat Chung SY, Lee KY, Chun EJ, et al. Comparison of stress perfusion MRI and SPECT for detection of myocardial ischemia in patients with angiographically proven three-vessel coronary artery disease. AJR Am J Roentgenol. 2010;195(2):356–62.CrossRefPubMed Chung SY, Lee KY, Chun EJ, et al. Comparison of stress perfusion MRI and SPECT for detection of myocardial ischemia in patients with angiographically proven three-vessel coronary artery disease. AJR Am J Roentgenol. 2010;195(2):356–62.CrossRefPubMed
23.
Zurück zum Zitat Melikian N, De Bondt P, Tonino P, et al. Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. J Am Coll Cardiol Intv. 2010;3(3):307–14.CrossRef Melikian N, De Bondt P, Tonino P, et al. Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. J Am Coll Cardiol Intv. 2010;3(3):307–14.CrossRef
24.
Zurück zum Zitat Segar DS, Brown SE, Sawada SG, Ryan T, Feigenbaum H. Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography. J Am Coll Cardiol. 1992;19(6):1197–202.CrossRefPubMed Segar DS, Brown SE, Sawada SG, Ryan T, Feigenbaum H. Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography. J Am Coll Cardiol. 1992;19(6):1197–202.CrossRefPubMed
25.
Zurück zum Zitat Herz SL, Hasegawa T, Makaryus AN, et al. Quantitative three-dimensional wall motion analysis predicts ischemic region size and location. Ann Biomed Eng. 2010;38(4):1367–76.CrossRefPubMedCentralPubMed Herz SL, Hasegawa T, Makaryus AN, et al. Quantitative three-dimensional wall motion analysis predicts ischemic region size and location. Ann Biomed Eng. 2010;38(4):1367–76.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Hachamovitch R, Rozanski A, Hayes SW, et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary? J Nucl Cardiol. 2006;13(6):768–78.CrossRefPubMed Hachamovitch R, Rozanski A, Hayes SW, et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary? J Nucl Cardiol. 2006;13(6):768–78.CrossRefPubMed
27.
Zurück zum Zitat Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012–24.CrossRefPubMed Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012–24.CrossRefPubMed
28.
Zurück zum Zitat Kim LJ, King 3rd SB, Kent K, et al. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. J Am Coll Cardiol Intv. 2009;2(5):384–92.CrossRef Kim LJ, King 3rd SB, Kent K, et al. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. J Am Coll Cardiol Intv. 2009;2(5):384–92.CrossRef
29.
Zurück zum Zitat Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91.CrossRefPubMed Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91.CrossRefPubMed
31.
Zurück zum Zitat Kern MJ, Samady H. Current concepts of integrated coronary physiology in the catheterization laboratory. J Am Coll Cardiol. 2010;55(3):173–85.CrossRefPubMed Kern MJ, Samady H. Current concepts of integrated coronary physiology in the catheterization laboratory. J Am Coll Cardiol. 2010;55(3):173–85.CrossRefPubMed
32.
Zurück zum Zitat Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995;92(11):3183–93.CrossRefPubMed Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995;92(11):3183–93.CrossRefPubMed
33.
Zurück zum Zitat Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103(24):2928–34.CrossRefPubMed Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103(24):2928–34.CrossRefPubMed
34.
Zurück zum Zitat Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49(21):2105–11.CrossRefPubMed Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49(21):2105–11.CrossRefPubMed
35.
Zurück zum Zitat Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.CrossRefPubMed Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.CrossRefPubMed
36.
Zurück zum Zitat Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177–84.CrossRefPubMed Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177–84.CrossRefPubMed
37.
Zurück zum Zitat Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816–21.CrossRefPubMed Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816–21.CrossRefPubMed
38.
Zurück zum Zitat De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMed De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMed
39.••
Zurück zum Zitat De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. The New England journal of medicine. 2014;371(13):1208–17. FAME 2 trial: Among patients with stable CAD, PCI to lesions with FFR ≤0.80 reduces the composite endpoint of death, non-fatal MI, and urgent revascularization compared to OMT alone, driven primarily by a reduction in urgent revascularization.CrossRefPubMed De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. The New England journal of medicine. 2014;371(13):1208–17. FAME 2 trial: Among patients with stable CAD, PCI to lesions with FFR ≤0.80 reduces the composite endpoint of death, non-fatal MI, and urgent revascularization compared to OMT alone, driven primarily by a reduction in urgent revascularization.CrossRefPubMed
40.
Zurück zum Zitat Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.PubMed Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.PubMed
41.•
Zurück zum Zitat Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol. 2014;64(16):1641–54. Ischemia does not exist as a dichotomous state but rather as a graded continuum. FFR provides a continuous and independent marker for MACE outcomes that can risk stratify prognosis as modulated by revascularization.CrossRefPubMed Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol. 2014;64(16):1641–54. Ischemia does not exist as a dichotomous state but rather as a graded continuum. FFR provides a continuous and independent marker for MACE outcomes that can risk stratify prognosis as modulated by revascularization.CrossRefPubMed
42.
43.
Zurück zum Zitat Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001;89(4):305–16.CrossRefPubMed Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001;89(4):305–16.CrossRefPubMed
44.
Zurück zum Zitat Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005;111(2):143–9.CrossRefPubMed Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005;111(2):143–9.CrossRefPubMed
45.
Zurück zum Zitat Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed
46.
Zurück zum Zitat Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61(10):1041–51.CrossRefPubMedCentralPubMed Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61(10):1041–51.CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Rade JJ. FFR-Guided PCI—FAME May Not Be So Fleeting after All. N Engl J Med. 2014;371(13):1251–3.CrossRefPubMed Rade JJ. FFR-Guided PCI—FAME May Not Be So Fleeting after All. N Engl J Med. 2014;371(13):1251–3.CrossRefPubMed
48.
Zurück zum Zitat Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13–8.CrossRefPubMed Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13–8.CrossRefPubMed
49.
Zurück zum Zitat De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “Normal” coronary angiography. Circulation. 2001;104(20):2401–6.CrossRefPubMed De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “Normal” coronary angiography. Circulation. 2001;104(20):2401–6.CrossRefPubMed
50.
Zurück zum Zitat Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131(1):19–27.CrossRefPubMed Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131(1):19–27.CrossRefPubMed
51.
Zurück zum Zitat Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation. 2002;105(25):2950–4.CrossRefPubMed Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation. 2002;105(25):2950–4.CrossRefPubMed
52.
Zurück zum Zitat Dorbala S, Di Carli MF, Beanlands RS, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol. 2013;61(2):176–84.CrossRefPubMedCentralPubMed Dorbala S, Di Carli MF, Beanlands RS, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol. 2013;61(2):176–84.CrossRefPubMedCentralPubMed
53.
Zurück zum Zitat Mancini GB, Hartigan PM, Bates ER, et al. Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial. Am Heart J. 2013;166(3):481–7.CrossRefPubMed Mancini GB, Hartigan PM, Bates ER, et al. Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial. Am Heart J. 2013;166(3):481–7.CrossRefPubMed
54.
Zurück zum Zitat Nijjer SS, Sen S, Petraco R, et al. Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Provides Virtual Intervention and Predicts Hemodynamic Outcome for Serial Lesions and Diffuse Coronary Artery Disease. J Am Coll Cardiol Intv. 2014;7(12):1386–96.CrossRef Nijjer SS, Sen S, Petraco R, et al. Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Provides Virtual Intervention and Predicts Hemodynamic Outcome for Serial Lesions and Diffuse Coronary Artery Disease. J Am Coll Cardiol Intv. 2014;7(12):1386–96.CrossRef
55.
Zurück zum Zitat Stanford University, Cardiovascular Research Center Aalst, Catharina Hospital Eindhoven, et al. A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Jun 04].Available from: http://ClinicalTrials.gov/show/NCT02100722 NLM Identifier: NCT02100722. Stanford University, Cardiovascular Research Center Aalst, Catharina Hospital Eindhoven, et al. A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Jun 04].Available from: http://​ClinicalTrials.​gov/​show/​NCT02100722 NLM Identifier:​ NCT02100722.
Metadaten
Titel
Role of Fractional-Flow Reserve in Guiding Percutaneous Revascularization in Stable Coronary Artery Disease
verfasst von
Nikolaos Kakouros
Jeffrey J. Rade
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 9/2015
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-015-0530-9

Weitere Artikel der Ausgabe 9/2015

Current Atherosclerosis Reports 9/2015 Zur Ausgabe

Lipid and Metabolic Effects of Gastrointestinal Surgery (R Cohen, Section Editor)

How Durable Are the Effects After Metabolic Surgery?

Cardiovascular Disease and Stroke (S Prabhakaran, Section Editor)

Imaging Acute Ischemic Stroke: Mapping Present and Future Clinical Practice

Cardiovascular Disease and Stroke (S Prabhakaran, Section Editor)

Use of Heparin in Acute Ischemic Stroke: Is There Still a Role?

Lipid and Metabolic Effects of Gastrointestinal Surgery (R Cohen, Section Editor)

Bariatric and Metabolic Surgery in Adolescents: a Path to Decrease Adult Cardiovascular Mortality

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.